Novo Nordisk’s Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo.
New data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline) data demonstrated that 160 weeks of treatment with Saxenda® (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).
